Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection

被引:91
作者
Avenoso, A [1 ]
Facciolà, G [1 ]
Salemi, M [1 ]
Spina, E [1 ]
机构
[1] Univ Messina, Policlin Univ, Sch Med, Inst Pharmacol, I-98125 Messina, Italy
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2000年 / 746卷 / 02期
关键词
risperidone; 9-hydroxyrisperidone;
D O I
10.1016/S0378-4347(00)00323-6
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple and sensitive high-performance Liquid chromatographic (HPLC) method with UV absorbance detection is described for the quantitation of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma, using clozapine as internal standard. After sample alkalinization with 1 ml of NaOH (2 M) the test compounds were extracted from plasma using diisopropyl ether-isoamylalcohol (99:1, v/v). The organic phase was back-extracted with 150 mu l potassium phosphate (0.1 M, pH 2.2) and 60 mu l of the acid solution was injected into a C-18 BDS Hypersil analytical column (3 mu m, 100x4.6 mm I.D.). The mobile phase consisted of phosphate buffer (0.05 M, pH 3.7 with 25% H3PO4)-acetonitrile (70:30, v/v), and was delivered at a flow-rate of 1.0 ml/min. The peaks were detected using a UV detector set at 278 nm and the total time for a chromatographic separation was about 4 min. The method was validated for the concentration range 5-100 ng/ml. Mean recoveries were 98.0% for risperidone and 83.5% for 9-hydroxyrisperidone. Intra- and inter-day relative standard deviations were less than 11% for both compounds, while accuracy, expressed as percent error, ranged from 1.6 to 25%. The limit of quantitation was 2 ng/ml for both analytes. The method shows good specificity with respect to commonly prescribed psychotropic drugs, and it has successfully been applied for pharmacokinetic studies and therapeutic drug monitoring. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:173 / 181
页数:9
相关论文
共 24 条
[1]   Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: Simultaneous determination by a high performance liquid chromatography with electrochemical detection [J].
Aravagiri, M ;
Marder, SR ;
Wirshing, D ;
Wirshing, WC .
PHARMACOPSYCHIATRY, 1998, 31 (03) :102-109
[2]   Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection [J].
Avenoso, A ;
Facciolá, G ;
Campo, GM ;
Fazio, A ;
Spina, E .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1998, 714 (02) :299-308
[3]   Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors [J].
Balant-Gorgia, AE ;
Gex-Fabry, M ;
Genet, C ;
Balant, LP .
THERAPEUTIC DRUG MONITORING, 1999, 21 (01) :105-115
[4]   Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study [J].
Bondolfi, G ;
Dufour, H ;
Patris, M ;
May, JP ;
Billeter, U ;
Eap, CB ;
Baumann, P .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (04) :499-504
[5]  
CHOUINARD G, 1993, CAN J PSYCHIAT, V38, pS89
[6]   Risperidone dose and blood level variability: Accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting [J].
Darby, JK ;
Pasta, DJ ;
Elfand, L ;
Dabiri, L ;
Clark, L ;
Herbert, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (06) :478-484
[7]  
Ereshefsky L, 1996, J CLIN PSYCHIAT, V57, P12
[8]   Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 [J].
Fang, J ;
Bourin, M ;
Baker, GB .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (02) :147-151
[9]  
HOFFMAN DW, 1995, PHARMACOTHERAPY, V15, P382
[10]   PHARMACOKINETICS OF THE NOVEL ANTIPSYCHOTIC AGENT RISPERIDONE AND THE PROLACTIN RESPONSE IN HEALTHY-SUBJECTS [J].
HUANG, ML ;
VANPEER, A ;
WOESTENBORGHS, R ;
DECOSTER, R ;
HEYKANTS, J ;
JANSEN, AAI ;
ZYLICZ, Z ;
VISSCHER, HW ;
JONKMAN, JHG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) :257-268